# 2026-09267: FDA Releases Guide for New Drugs Against C. Diff Infections

2026-09267, Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-11, effective 2026-05-11 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09267
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09267
- Title: Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 25578
- Published: 2026-05-11
- Effective: 2026-05-11
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Releases Guide for New Drugs Against C. Diff Infections

## Summary

The FDA just released new guidance to help drug makers create medicines that treat, prevent, or stop Clostridioides difficile infections (CDI) from coming back. This update affects companies working on CDI drugs and aims to speed up safe, effective treatments reaching patients. The guidance is official as of May 11, 2026, and could save time and money by clarifying what’s needed for drug approval.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention." The purpose of this guidance is to assist sponsors in the clinical development of drugs to support an indication of treatment, reduction of recurrence, or prevention of Clostridioides difficile infection (CDI). This guidance finalizes the draft guidance titled "Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention" issued on October 28. 2022.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09267 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/11/2026-09267/clostridioides-difficile-infection-developing-drugs-for-treatment-reduction-of-recurrence-or)
- [2026-09267 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-11/pdf/2026-09267.pdf)

## Related
- [Previous: 2026-09265, 60-Day Notice of Proposed Information Collection: Resident Opportunities and Se…](https://policyrisk.com/federal-register/2026-09265)
- [Next: 2026-09268, Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability](https://policyrisk.com/federal-register/2026-09268)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09267 (as of 2026-06-08).
